HBK Sorce Advisory’s Agile Therapeutics AGRX Stock Holding History

HBK Sorce Advisory’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18	Closed	-$7K	–	573
2022 Q1	$7K	Hold	18	–	–	﹤0.01%	552
2021 Q4	$17K	Hold	18	–	–	﹤0.01%	593
2021 Q3	$34K	Hold	18	–	–	﹤0.01%	586
2021 Q2	$47K	Buy	18 +5	+38%	+$16.5K	﹤0.01%	586
2021 Q1	$52K	Buy	+13	New	+$70.3K	﹤0.01%	538

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HBK Sorce Advisory's AGRX Position: Q2 2022 in Review

HBK Sorce Advisory sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 18 shares — an estimated $7K sold.

HBK Sorce Advisory first reported a position in AGRX in Q1 2021 and held it in 5 quarters. The position peaked at $52K in Q1 2021. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

HBK Sorce Advisory reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
HBK Sorce Advisory sold 18 Agile Therapeutics shares in Q2 2022, an estimated $7K.
HBK Sorce Advisory first reported a position in Agile Therapeutics in Q1 2021 and held it in 5 quarters.
HBK Sorce Advisory's Agile Therapeutics position peaked at $52K in Q1 2021.
19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on HBK Sorce Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.